二巯丁二酸临床应用进展  

Progression on Clinical Application of Succimer (DMSA, Di-mercaptosuccinic Acid)

作　　者：吴慧[1] 王簃兰[2] 

机构地区：[1]中国科学院上海药物研究所,上海201203 [2]复旦大学公共卫生学院,上海200032

出　　处：《环境与职业医学》2010年第9期568-570,共3页Journal of Environmental and Occupational Medicine

摘　　要：二巯丁二酸(di-mercaptosuccinic acid,DMSA)是广谱金属解毒剂,是中国首个被美国仿制、经美国食品药品与监督管理局批准上市的药物。由中科院上海药物研究所丁光生等于1957年发现,应用于锑、汞、铅、砷等金属中毒及肝豆状核变性治疗。20世纪90年代以前的研究,丁光生等已在1989年、1991年进行了完整的综述。本文主要对此后的临床研究进行介绍。Succimer（DMSA, Di-mercapto-succinic acid）is an antidote against poisoning of broad-spectrum metals. It was first synthesized, studied, and reported by Chinese scientist Dr. Ding Guangsheng 1957, and then being imitated in United States, and approved for marketing by FDA. It was used for treatment intoxication of antimony, mercury, lead, arsenic, other metal poisons, and Wilson’s disease. Its application and clinical feature prior to 1990’s have been summarized by Dr. Ding Guangsheng in 1989 and 1991. This paper reviews the consequent progression in clinical application and study since then.

关 键 词：二巯丁二酸 金属中毒 肝豆状核变性 

分 类 号：R135.1[医药卫生—劳动卫生]